NCT07123896

Brief Summary

The goal of this prospective, observational registry study is to evaluate the long-term effectiveness, safety, and impact of different kinds of treatment on the quality of life across diverse arrhythmia subtypes and patient populations in hospitalized adults with cardiac arrhythmias (including atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular arrhythmias) undergoing routine clinical care.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
52mo left

Started Aug 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Aug 2025Jul 2030

First Submitted

Initial submission to the registry

July 29, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

August 14, 2025

Completed
10 days until next milestone

Study Start

First participant enrolled

August 24, 2025

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 24, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 24, 2030

Last Updated

August 14, 2025

Status Verified

August 1, 2025

Enrollment Period

4.9 years

First QC Date

July 29, 2025

Last Update Submit

August 12, 2025

Conditions

Arrhythmia

Outcome Measures

Primary Outcomes (2)

  • Arrhythmia recurrence

    Recurrence of the arrhythmia after treatment

    1 year

  • All-cause death

    Death due to any reason

    1 year

Secondary Outcomes (8)

  • Arrhythmia recurrence

    5 year

  • All-cause death

    5 year

  • Cardiovascular death

    1 year

  • Cardiovascular death

    5 year

  • Heart failure

    1 year

  • +3 more secondary outcomes

Study Arms (1)

Treatment

Device: Normal treatment with catheter ablation or medicineDrug: Drug Treatment

Interventions

Normal treatment with catheter ablation or medicineDEVICE

Routine clinical care with catheter ablation and/or medicine; real-world clinical cases

Treatment
Drug TreatmentDRUG

Routine clinical care with medicine; real-world clinical cases

Treatment

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients hospitalized for various types of arrhythmia

You may qualify if:

  • Patients hospitalized for any type of arrhythmia

You may not qualify if:

  • Patients currently participating in interventional clinical trials that may confound data collection or outcome assessment in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Deyong Long

Beijing, China

Location

MeSH Terms

Conditions

Arrhythmias, Cardiac

Interventions

Catheter AblationDosage Forms

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Radiofrequency AblationRadiofrequency TherapyTherapeuticsAblation TechniquesSurgical Procedures, OperativePharmaceutical PreparationsTechnology, PharmaceuticalInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2025

First Posted

August 14, 2025

Study Start

August 24, 2025

Primary Completion (Estimated)

July 24, 2030

Study Completion (Estimated)

July 24, 2030

Last Updated

August 14, 2025

Record last verified: 2025-08

Locations

CN(1)